Immunoglobulins in Neonates with Rhesus Hemolytic Disease of the Fetus and Newborn: Long-Term Outcome in a Randomized Trial | Zendy

Jeanine M.M. van Klink | Zendy; Suzanne J. van Veen | Zendy; Vivianne E.H.J. SmitsWintjens | Zendy; Irene T.M. Lindenburg | Zendy; Monique Rijken | Zendy; Dick Oepkes | Zendy; Enrico Lopriore | Zendy

Open Access

Immunoglobulins in Neonates with Rhesus Hemolytic Disease of the Fetus and Newborn: Long-Term Outcome in a Randomized Trial

Author(s) -

Jeanine M.M. van Klink,

Suzanne J. van Veen,

Vivianne E.H.J. SmitsWintjens,

Irene T.M. Lindenburg,

Monique Rijken,

Dick Oepkes,

Enrico Lopriore

Publication year - 2015

Publication title -

fetal diagnosis and therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.976

H-Index - 60

eISSN - 1421-9964

pISSN - 1015-3837

DOI - 10.1159/000434718

Subject(s) - medicine , pediatrics , randomized controlled trial , exchange transfusion , cerebral palsy , placebo , incidence (geometry) , pregnancy , surgery , physical therapy , physics , alternative medicine , pathology , biology , optics , genetics

Prophylactic intravenous immunoglobulin (IVIg) does neither reduce the need for exchange transfusion nor the rates of other adverse neonatal outcomes in neonates with rhesus hemolytic disease of the fetus and newborn (rhesus HDFN) according to our randomized controlled trial analysis. Our objective was to assess the long-term neurodevelopmental outcome in the children included in the trial and treated with either IVIg or placebo.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research